Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability study of oral vericiguat versus intravenous 14C-labeled vericiguat microdose in healthy men
NL-OMON42434Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vericiguat in heart failure (HF), sponsored by Bayer. Primary endpoints: AUC divided by dose (AUC/D) of vericiguat and 14C-labeled vericiguat, Cmax divided by dose (Cmax/D) of vericiguat and 14C-labeled vericiguat and 1 more. Started Oct 2015; status: active, not recruiting.
02
Drugs
vericiguat
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NL-OMON42434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42434.